Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
EMBC
Upturn stock ratingUpturn stock rating

Embecta Corp (EMBC)

Upturn stock ratingUpturn stock rating
$9.69
Last Close (24-hour delay)
upturn advisory
PASS
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

06/30/2025: EMBC (1-star) is currently NOT-A-BUY. Pass it for now.

Upturn Star Rating

rating

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

Number of Analysts

rating

5 Analysts rated it

Moderately tracked stock, growing coverage, gaining market and investor attention.

1 Year Target Price $18.67

1 Year Target Price $18.67

Analysts Price Target For last 52 week
$18.67Target price
Low$9.2
Current$9.69
high$20.8

Analysis of Past Performance

Type Stock
Historic Profit -3.15%
Avg. Invested days 30
Today’s Advisory PASS
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 2.0
Stock Returns Performance Upturn Returns Performance 1.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 06/30/2025

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 563.39M USD
Price to earnings Ratio 10.83
1Y Target Price 18.67
Price to earnings Ratio 10.83
1Y Target Price 18.67
Volume (30-day avg) 5
Beta 1.08
52 Weeks Range 9.20 - 20.80
Updated Date 06/29/2025
52 Weeks Range 9.20 - 20.80
Updated Date 06/29/2025
Dividends yield (FY) 6.22%
Basic EPS (TTM) 0.89

Analyzing Revenue: Products, Geography and Growth

Revenue by Products

Revenue by Geography

Geography revenue - Year on Year

Earnings Date

Report Date -
When -
Estimate -
Actual -

Profitability

Profit Margin 4.89%
Operating Margin (TTM) 30.35%

Management Effectiveness

Return on Assets (TTM) 2.53%
Return on Equity (TTM) -

Valuation

Trailing PE 10.83
Forward PE -
Enterprise Value 1905585777
Price to Sales(TTM) 0.52
Enterprise Value 1905585777
Price to Sales(TTM) 0.52
Enterprise Value to Revenue 1.77
Enterprise Value to EBITDA 9.21
Shares Outstanding 58442500
Shares Floating 57228657
Shares Outstanding 58442500
Shares Floating 57228657
Percent Insiders 0.47
Percent Institutions 101.44

Analyst Ratings

Rating 3
Target Price 18.67
Buy -
Strong Buy 1
Buy -
Strong Buy 1
Hold 3
Sell 1
Strong Sell -
Strong Sell -

ai summary icon Upturn AI SWOT

Embecta Corp

stock logo

Company Overview

overview logo History and Background

Embecta Corp. was spun off from Becton, Dickinson and Company (BD) in April 2022. It focuses exclusively on diabetes care products, carrying forward BD's legacy in this sector. The company is relatively young as a standalone entity.

business area logo Core Business Areas

  • Insulin Delivery: Embecta Corp. primarily focuses on insulin delivery devices, including pen needles and syringes used by people with diabetes to administer insulin.

leadership logo Leadership and Structure

The leadership team consists of experienced executives with backgrounds in medical devices and pharmaceuticals. The organizational structure is designed to support its focus on diabetes care.

Top Products and Market Share

overview logo Key Offerings

  • Pen Needles: Embecta offers a wide range of pen needles compatible with various insulin pens. Market share information is difficult to pinpoint exactly, but they are a major player globally in the pen needle market. Competitors include Novo Nordisk, B. Braun, and Owen Mumford.
  • Syringes: Embecta manufactures insulin syringes. Market share information is difficult to pinpoint exactly, but they are a major player globally in the insulin syringe market. Competitors include B. Braun, and Nipro.

Market Dynamics

industry overview logo Industry Overview

The diabetes care market is driven by the increasing prevalence of diabetes globally. The industry is competitive, with companies offering various insulin delivery solutions and glucose monitoring systems.

Positioning

Embecta Corp. holds a strong position in the insulin delivery market, leveraging its history as part of BD. Its competitive advantages include its established brand, global distribution network, and focus on diabetes care.

Total Addressable Market (TAM)

The global diabetes care devices market is projected to reach hundreds of billions of dollars. Embecta is positioned to capture a portion of this market through its insulin delivery products.

Upturn SWOT Analysis

Strengths

  • Established Brand
  • Global Distribution Network
  • Focus on Diabetes Care
  • High-Volume Manufacturing Capabilities
  • Strong customer relationships

Weaknesses

  • Dependence on Insulin Delivery Market
  • Relatively new standalone company
  • Limited product diversification
  • High debt levels

Opportunities

  • Expanding into New Markets
  • Developing Innovative Insulin Delivery Devices
  • Acquiring Complementary Businesses
  • Partnerships with Insulin Manufacturers

Threats

  • Increased Competition
  • Pricing Pressures
  • Technological Advancements (e.g., insulin pumps, continuous glucose monitors)
  • Changes in Healthcare Regulations
  • Generic competition

Competitors and Market Share

competitor logo Key Competitors

  • NVO
  • BDX
  • MRK

Competitive Landscape

Embecta faces competition from established medical device companies and pharmaceutical giants. Its focus on insulin delivery gives it an advantage in this specific niche, but it needs to innovate to maintain its market position.

Growth Trajectory and Initiatives

Historical Growth: Historical growth data is limited due to its recent spin-off. Provide Placeholder values here.

Future Projections: Detailed financial analysis requires real-time data. Provide Placeholder values here.

Recent Initiatives: Detailed financial analysis requires real-time data. Provide Placeholder values here.

Summary

Embecta Corp. is a relatively new company specializing in diabetes care, particularly insulin delivery systems. It benefits from a strong brand legacy and global presence. However, the company faces challenges including competition and needs to watch out for rapid technological advancements which could diminish its market share. Overall, Embecta has potential for growth but needs to strategically navigate a dynamic market.

Peer Comparison

Sources and Disclaimers

Data Sources:

  • Company SEC Filings
  • Industry Reports
  • Analyst Estimates

Disclaimers:

This analysis is based on publicly available information and is not financial advice. Market conditions and company performance can change rapidly. Verify information with independent sources.

Upturn AI SummarizationUpturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI SummarizationUpturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI SummarizationUpturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI SummarizationUpturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.

About Embecta Corp

Exchange NASDAQ
Headquaters Parsippany, NJ, United States
IPO Launch date 2022-04-01
President, CEO & Director Mr. Devdatt Kurdikar Ph.D.
Sector Healthcare
Industry Medical Instruments & Supplies
Full time employees 2000
Full time employees 2000

Embecta Corp., a medical device company, focuses on the provision of various solutions to enhance the health and wellbeing of people living with diabetes in the United States and internationally. The company's products include pen needles, syringes, and safety injection devices, as well as digital applications to assist people with managing patient's diabetes. It primarily sells its products to wholesalers and distributors. The company was formerly known as Berra Newco, Inc. Embecta Corp. was founded in 1924 and is headquartered in Parsippany, New Jersey.